Dalia R. Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dalia R. Ibrahim has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Iva Durdanovic
Department of Drug Discovery and Development, Harrison School of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, AL 36849, USA
2 shared publications - Oula Alkhalifa
Department of Bioengineering, Adana Alparslan Türkeş Science and Technology University, Adana 01250, Turkey
2 shared publications - Sofia Maragkou
Department of Neuroanatomy, Institute of Anatomy and Cell Biology, Medical School, Saarland University, 66421 Homburg, Germany
2 shared publications Amer E. Alkhalifa
Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, USA
1 shared publication- Amer E. Alkhalifa
Department of Drug Discovery and Development, Harrison School of Pharmacy, Pharmacy Research Building, Auburn University, Auburn, AL 36849, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 3 June 2025
- Published by MDPI AG in Journal of Dementia and Alzheimer's Disease
- Vol. 2 (2) , 17
Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease: Insights into Pathophysiology and Treatment
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. Increasing evidence highlights oxidative stress as a pivotal contributor to AD pathogenesis, closely associated with hallmark features such as amyloid-β (Aβ) plaque accumulation, tau hyperphosphorylation, and synaptic dysfunction. This review aims to elucidate the mechanisms by which oxidative stress contributes to AD and to evaluate emerging therapeutic strategies targeting oxidative damage. Methods: We conducted an extensive literature search using PubMed and Google Scholar for studies published between 1994 and 2024. This narrative review integrates findings from in vitro, in vivo, and clinical studies focusing on oxidative stress, mitochondrial dysfunction, and their roles in AD to provide a comprehensive overview of the current research landscape. Results: ROS and RNS levels are significantly elevated in aging and AD-affected brains, leading to oxidative damage to lipids, proteins, and DNA, which compromises neuronal function and structure. Mitochondrial dysfunction plays a key role by amplifying ROS production, impairing ATP synthesis, and accelerating neurodegeneration. Oxidative stress also interacts with central AD pathologies, including Aβ aggregation, tau hyperphosphorylation, and synaptic dysfunction, creating a vicious cycle of neuronal injury. Although traditional antioxidant therapies have shown limited efficacy in clinical settings, often due to poor bioavailability, limited BBB penetration, and systemic distribution, novel strategies such as mitochondrial-targeted antioxidants and combination therapies have demonstrated improved outcomes in preclinical models. Conclusions: Oxidative stress plays a multifaceted role in the progression of AD, necessitating comprehensive therapeutic approaches. Future treatments should focus on targeting multiple aspects of oxidative stress, particularly mitochondrial dysfunction, to enhance clinical outcomes and slow neurodegeneration in AD patients.
- 3 June 2025
- Published by MDPI AG in Journal of Dementia and Alzheimer's Disease
- Vol. 2 (2) , 17
Top Cited PapersOpen AccessOxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease: Insights into Pathophysiology and Treatment
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. Increasing evidence highlights oxidative stress as a pivotal contributor to AD pathogenesis, closely associated with hallmark features such as amyloid-β (Aβ) plaque accumulation, tau hyperphosphorylation, and synaptic dysfunction. This review aims to elucidate the mechanisms by which oxidative stress contributes to AD and to evaluate emerging therapeutic strategies targeting oxidative damage. Methods: We conducted an extensive literature search using PubMed and Google Scholar for studies published between 1994 and 2024. This narrative review integrates findings from in vitro, in vivo, and clinical studies focusing on oxidative stress, mitochondrial dysfunction, and their roles in AD to provide a comprehensive overview of the current research landscape. Results: ROS and RNS levels are significantly elevated in aging and AD-affected brains, leading to oxidative damage to lipids, proteins, and DNA, which compromises neuronal function and structure. Mitochondrial dysfunction plays a key role by amplifying ROS production, impairing ATP synthesis, and accelerating neurodegeneration. Oxidative stress also interacts with central AD pathologies, including Aβ aggregation, tau hyperphosphorylation, and synaptic dysfunction, creating a vicious cycle of neuronal injury. Although traditional antioxidant therapies have shown limited efficacy in clinical settings, often due to poor bioavailability, limited BBB penetration, and systemic distribution, novel strategies such as mitochondrial-targeted antioxidants and combination therapies have demonstrated improved outcomes in preclinical models. Conclusions: Oxidative stress plays a multifaceted role in the progression of AD, necessitating comprehensive therapeutic approaches. Future treatments should focus on targeting multiple aspects of oxidative stress, particularly mitochondrial dysfunction, to enhance clinical outcomes and slow neurodegeneration in AD patients.
- Open Access
- 17 March 2025
- Published by MDPI AG in Preprints.org
Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease: Insights into Pathophysiology and Treatment
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily marked by cognitive decline and memory loss. Oxidative stress (OS) has emerged as a critical factor in AD pathogenesis, contributing to hallmark features such as amyloid-β (Aβ) plaque formation, tau hyperphosphorylation, and synaptic dysfunction. This review delves into the complex mechanisms driving reactive oxygen species (ROS) production, including mitochondrial dysfunction, metal ion dysregulation, and impaired antioxidant defenses, and examines their damaging effects on neuronal integrity. Elevated ROS levels in the aging brain cause oxidative modifications to lipids, proteins, and DNA, leading to neuronal atrophy, synapse loss, and cognitive impairment. Mitochondrial dysfunction amplifies OS by disrupting cellular energy metabolism and further promoting neurodegeneration through excessive ROS generation and reduced ATP production. Despite strong evidence linking OS to AD, clinical trials with antioxidant therapies have yielded inconsistent results. However, emerging therapeutic strategies, including targeted mitochondrial antioxidants and combination therapies, offer promising avenues for mitigating OS-related damage. This review emphasizes the need for a multifaceted therapeutic approach to address the complexity of OS in AD, with the goal of developing more effective treatments and improving patient outcomes.
- 17 March 2025
- Published by MDPI AG in Preprints.org
Open AccessOxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease: Insights into Pathophysiology and Treatment
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily marked by cognitive decline and memory loss. Oxidative stress (OS) has emerged as a critical factor in AD pathogenesis, contributing to hallmark features such as amyloid-β (Aβ) plaque formation, tau hyperphosphorylation, and synaptic dysfunction. This review delves into the complex mechanisms driving reactive oxygen species (ROS) production, including mitochondrial dysfunction, metal ion dysregulation, and impaired antioxidant defenses, and examines their damaging effects on neuronal integrity. Elevated ROS levels in the aging brain cause oxidative modifications to lipids, proteins, and DNA, leading to neuronal atrophy, synapse loss, and cognitive impairment. Mitochondrial dysfunction amplifies OS by disrupting cellular energy metabolism and further promoting neurodegeneration through excessive ROS generation and reduced ATP production. Despite strong evidence linking OS to AD, clinical trials with antioxidant therapies have yielded inconsistent results. However, emerging therapeutic strategies, including targeted mitochondrial antioxidants and combination therapies, offer promising avenues for mitigating OS-related damage. This review emphasizes the need for a multifaceted therapeutic approach to address the complexity of OS in AD, with the goal of developing more effective treatments and improving patient outcomes.